Drugs in MeSH Category Coccidiostats

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	SULFADIAZINE	sulfadiazine	TABLET;ORAL	040091-001	Jul 29, 1994		RX	No	Yes
Lilly	SULFADIAZINE	sulfadiazine	TABLET;ORAL	004122-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Chartwell Molecular	SULFADIAZINE	sulfadiazine	TABLET;ORAL	080084-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Everylife	SULFADIAZINE	sulfadiazine	TABLET;ORAL	080088-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Patent Landscape for Coccidiostats (NLM MeSH Class)

Last updated: April 25, 2026

What counts as “coccidiostats” in this market?

In NLM MeSH, Coccidiostats is a drug class used to prevent, control, or treat coccidiosis (protozoal infections) in animals, especially poultry and other livestock. The commercial coccidiostat toolkit is dominated by:

• Ionophores (produced widely, used as feed additives)
• Synthetic/nitro-heterocyclics and related agents (used as feed or treatment depending on compound and region)
• Shuttle approaches and programs (rotations and combinations to manage resistance)

This market is largely feed- and program-driven rather than strictly patient-therapy driven, which shapes both pricing power and how patents translate into revenue.

---

How does market demand behave for coccidiostats?

Coccidiostats are sold into animal production systems where dosing is tied to production cycles, not long-tail chronic use. Demand is driven by:

1. Poultry inventory cycles
   • Broiler and layer production volumes drive annual tonnage of medicated feed.
2. Resistance management needs
   • Coccidia resistance pressures farmers and integrators to rotate products, shift programs, or adopt combinations.
3. Regulatory and labeling constraints
   • Compounds approved for specific species and regions determine install-base.
4. Feed cost and performance economics
   • End-users evaluate coccidiostat ROI through improvements in feed conversion ratio, weight gain, mortality reduction, and uniformity.
5. Biosecurity and husbandry baselines
   • Where farm-level controls are weak, prophylactic use increases.

---

Where is value created: active ingredient vs. program vs. feed formulation?

The market’s value chain has three layers:

• Active ingredient supply (manufacturers and chemical intermediates)
• Premix and medicated feed formulation (feed mills)
• On-farm program execution (rotation schedules and inclusion rates)

Patents typically cover active molecules, specific uses, or compositions of matter, but in practice, feed programs and inclusion timing often dominate near-term switching decisions. That makes “patent life remaining” less predictive of commercial outcomes than:

• Regulatory status (what is authorized)
• Resistance track record
• Customer-specific performance under local strains

---

How do competing technologies pressure pricing and margins?

Competition works through four mechanisms:

1. Multi-source generics for off-patent actives
   • Ionophores and older synthetic agents often have extensive supply chains, which compresses pricing.
2. Switching costs are moderate
   • Farmers can change premix suppliers if performance and withdrawal/regulatory constraints remain acceptable.
3. Integrator and retailer scale
   • Large poultry integrators negotiate on cost-per-ton of medicated feed and consistency of supply.
4. Resistance changes product mix
   • Resistance can shift demand to specific chemistry faster than formal patent expiry.

The net effect is that margins tend to concentrate around differentiated products, new approvals, and registered programs, not around long-term exclusive rights to legacy actives.

---

What is the current patent landscape shape in coccidiostats?

Across the coccidiostat sector, the patent landscape typically shows:

• Dense early wave coverage for foundational small molecules
• Subsequent process and formulation patents (feed premix manufacturing, stabilization, granulation, coating)
• Second-generation improvements (dosage ranges, combinations, species-specific claims, resistance-related use)
• Narrow or hard-to-enforce claims when prior art is broad and use claims are constrained by regulation and labeling practice

For business planning, the practical read is:

• Molecule exclusivity often ends before the technology loses commercial relevance (because approvals persist and branded programs can outlast patent claims).
• Residual exclusivity comes from regulatory exclusivity, manufacturing know-how, registered premix specifications, and combination strategies, not solely from composition-of-matter patents.

---

Which major coccidiostats anchor the market?

The market centers on widely used coccidiostats, typically marketed as:

• Ionophores
• Chemically defined anticoccidials (synthetic and nitro-based agents)
• Combination programs where two actives address multiple resistance profiles

While the patent portfolio depends on the specific chemistry, the commercial reality is that regulatory approvals and resistance performance determine adoption more than marketing claims alone.

---

How do patents map to revenue in this category?

In coccidiostats, patents translate into revenue through one or more of these channels:

• Direct ingredient exclusivity: when active ingredients are protected and regulatory authorization prevents easy substitution.
• Regulatory-linked data/approval exclusivity: where the approval pathway creates a practical delay for generic entry.
• Combination and dosing regimens: when claims are drafted around specific inclusion schedules or combination ratios that regulators and customers adopt.
• Manufacturing/process advantages: where patents protect production yield, stability, or granule performance.

However, enforceability often faces barriers:

• Prior art breadth
• Regulatory alignment issues for method-of-use claims
• Claim narrowing due to obviousness and design-around

---

What is the typical lifecycle of a coccidiostat product?

A representative lifecycle for a new coccidiostat program in the sector often follows:

1. Discovery and early filing
2. Regulatory package build
3. Launch with performance trials
4. Program adoption and rotation into farm schedules
5. Patent expiry with generic ingredient competition
6. Retention via registered combinations and supplier lock-in

Because usage is prophylactic in many systems, adoption can become sticky once a program has delivered predictable performance and quality controls.

---

Where are enforceable “last-mile” protections most likely to exist?

Even when composition-of-matter patents expire, protection may continue via:

• Process claims for specific manufacturing steps
• Formulation patents for premix stability, anti-caking, and granule characteristics
• Combination patents that specify ratios or sequence-administration patterns
• Species and efficacy-window claims that align with regulatory labels

For investors and R&D strategists, this means the most actionable IP is often found in the late-stage portfolio (formulation/process and combination improvements), not only in the original molecule.

---

How do regulatory structures affect patent risk and generics timing?

Coccidiostats are regulated as feed additives or veterinary drugs depending on jurisdiction. Key effects on generics:

• Approval status gates entry: even with patent expiry, generic manufacturers must obtain approvals that mirror the authorized safety and efficacy data packages.
• Labeling constraints: if approved use instructions are narrow, generic substitution may be slower where claims and labels differ.
• Species-specific authorizations: a compound may remain approved for some species/regions while others require separate approvals.

This tends to create a practical “exclusivity window” beyond the strict patent calendar.

---

What should a patent sprint focus on in this class?

For an IP diligence or competitive intelligence program, the highest-yield sprint targets are:

• Latest priority filings related to:
  • combination products
  • dosing regimens
  • premix formulation
  • process improvements with yield and stability claims
• Ownership and assignee mapping
  • identify whether filings cluster under feed additive specialists versus pharma-style discovery organizations
• Family breadth
  • identify which jurisdictions were actually pursued for enforcement
• Regulatory reference links
  • capture where approval depends on specific product dossiers tied to proprietary submissions

---

Key Takeaways

• Coccidiostat demand is program and production-cycle driven, making adoption and resistance management central to revenue performance.
• The patent landscape typically evolves from composition-of-matter into process, formulation, and combination protections, which are often more relevant to late-stage competition.
• Market switching is influenced by regulatory approvals, local resistance profiles, and performance reliability, which can outlast strict molecule patent expiry.
• Competitive entry timing is shaped by both patent expiry and approval gating, so the commercial “exclusivity window” can extend beyond the legal one.

---

FAQs

1) What drives purchase decisions for coccidiostats?

ROI in poultry/livestock production, resistance performance, consistent supply of authorized premixes, and fit with farm rotation programs.

2) Do patents meaningfully control supply after composition-of-matter expiry?

Often not at the molecule level, but late-stage process/formulation/combination claims and regulatory linkage can slow substitution.

3) Are coccidiostats mainly a poultry market?

Poultry is the dominant use case in practice, with demand tied to broiler/layer production cycles.

4) Why do resistance trends matter to IP strategy?

Resistance changes which chemistries and combinations remain effective, shifting demand to products that hold the best field performance, regardless of older patent status.

5) What is the most actionable IP to monitor for competition?

New filings near the end of product life that cover premix formulation, manufacturing processes, and combination regimens, plus jurisdictional family pursuit and assignee changes.

---

References

[1] National Library of Medicine. MeSH Browser. Coccidiostats. https://meshb.nlm.nih.gov/